ASC37 has shown to have an average observed half-life of around 17 days in head-to-head non-human primate studies, which is 7 times longer than retatrutide. This indicates its potential for once-monthly subcutaneous dosing in humans. Additionally, ASC37 exhibited approximately 5-, 4-, and 4-fold greater in vitro activity compared to other substances.